其中，第三季度公司营收5.69亿元，同比下滑16.01%；归母净利润为4069.71万元，同比下滑26.22%；扣非净利润为3777.15万元，同比将逾三成。 公开资料显示，亚宝药业集团股份有限公司集药品和大健康产品的研发、生产、销售、物流及中药材种植于一体，拥有"丁桂儿脐贴"等明星产品。 据2024年年报披露，亚宝药业丁桂儿脐贴销量同比下滑10.60%至8582.91万贴，与2023年相比少卖1017.92万贴。另外，对于今年上半年营业收入同比减 少，亚宝药业称主要系本期消肿止痛贴、盐酸倍他司汀注射液、儿童清咽解热口服液等产品及医药批发业务收入减少。 10月24日盘后，亚宝药业（600351）披露三季报，公司前三季度营收净利双双下滑。 事实上，近年来业绩持续上涨的亚宝药业进入2025年后显露疲态，Choice数据显示，今年一季度及上半年公司净利润分别下滑4.45%及2.99%，其中第二季 度下滑0.57%。营收方面更是从去年开始就出现下滑，今年前两个季度分别同比减少20.32%及21.95%。 三季报显示，亚宝药业第三季度利润总额大幅下滑逾四成，公司称主要为期内SY-009研发项目终止，计提资产减值准备所致 ...

Core Viewpoint - The company has decided to terminate the clinical research and development of SY-009, a sodium-glucose co-transporter 1 inhibitor intended for the treatment of type 2 diabetes, and will fully recognize an asset impairment provision according to accounting standards [1] Financial Summary - Total R&D investment in SY-009 amounts to 87.87 million yuan, with 32.08 million yuan recognized as expenses and 55.79 million yuan capitalized [1] - The asset impairment provision will reduce the company's total profit for the year 2025 by 55.79 million yuan [1]

Core Viewpoint - The company has decided to terminate the clinical research and development of SY-009 capsules, leading to a full impairment of the capitalized R&D amount of 55.7933 million yuan, which will reduce the company's total profit for 2025 by the same amount [1] Group 1: Project Termination - The company announced the termination of the clinical research for SY-009 capsules [1] - SY-009 is a sodium-glucose co-transporter 1 inhibitor aimed at reducing postprandial glucose absorption for the treatment of type 2 diabetes [1] Group 2: Financial Impact - The impairment of the R&D capitalized amount of 55.7933 million yuan will directly impact the company's profit for the year 2025 [1] Group 3: Clinical Trial Results - Phase II clinical trial results indicated a relationship between dosage and efficacy, but the primary efficacy endpoint was not met [1] - The company faces significant uncertainty regarding further R&D investments and the time required to conduct additional trials [1]